Safety and efficacy of co-transplantation of hematopoietic stem cells combined with human umbilical cord-derived mesenchymal stem cells in children with severe aplastic anemia: a single-center experience

Abstract

Objectives: The most important problems that limit the effectiveness of allogeneic hematopoietic stem cell transplantation in patients with severe aplastic anemia are graft failure and graft-versus-host disease. Mesenchymal stem cells can support normal hematopoiesis and prevent graft-versus-host disease. We aimed to analyze the effects of combined transplant of human umbilical cord-derived mesenchymal stem cells and matched donor allogeneic hematopoietic stem cells in children with severe aplastic anemia. Materials and Methods: We retrospectively examined 15 pediatric patients with severe aplastic anemia who received fludarabine-based reduced intensity conditioning regimen and intravenously infused human umbilical cord-derived mesenchymal stem cells at a dose of 1 x 106/kg recipient body weight within 12 to 18 hours before hematopoietic stem cells infusion. We evaluated the engraftment rate, the frequency and severity of graft-versus-host disease, and the overall survival rate. Results: No patients had adverse events related to intravenously human umbilical cord-derived mesenchymal stem cells infusion. All patients achieved successful engraftment and sustained donor chimerism. The median time for neutrophil and platelet engraftment was 14 and 25 days, respectively. The frequency was 20% for grade III/IV acute graft-versus-host disease and 15.3% for chronic graft-versus-host disease. Patients were followed- up for a median of 33 months (range, 2-89 months). The 5-year overall survival rate was 80%. Conclusions: Combined transplant of matched donor hematopoietic stem cells with human umbilical cord- derived mesenchymal stem cells is safe in pediatric patients with severe aplastic anemia. The achievement of engraftment in all of our patients and the acceptable frequency of acute and chronic graft-versus-host disease and survival rate are encouraging.